Summary
1.82 -0.10(-4.97%)09/16/2024
Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics Inc. (ESPR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.97 | 14.55 | 3.99 | -35.05 | -13.70 | 46.51 | -94.83 | -86.97 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.82 | |
| Open | 1.89 | |
| High | 1.90 | |
| Low | 1.79 | |
| Volume | 1,636,695 | |
| Change | -0.10 | |
| Change % | -4.97 | |
| Avg Volume (20 Days) | 2,709,769 | |
| Volume/Avg Volume (20 Days) Ratio | 0.60 | |
| 52 Week Range | 0.70 - 3.40 | |
| Price vs 52 Week High | -46.62% | |
| Price vs 52 Week Low | 159.29% | |
| Range | 6.18 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 375 | |
| EBIDTA | -155,399,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -4.7800 | |
| WallStreet Target Price | 7.41 | |
| Book Value | -3.8490 | |
| Earnings Per Share | -2.0300 | |
| EPS Estimate Current Quarter | 0.0500 | |
| EPS Estimate Next Quarter | -0.2100 | |
| EPS Estimate Current Year | -0.3700 | |
| EPS Estimate Next Year | 0.2500 | |
| Diluted EPS (TTM) | -2.0300 | |
| Revenues | ||
| Profit Marging | -1.7987 | |
| Operating Marging (TTM) | -1.3137 | |
| Return on asset (TTM) | -0.4286 | |
| Return on equity (TTM) | -2.6079 | |
| Revenue TTM | 116,334,000 | |
| Revenue per share TTM | 1.1280 | |
| Quarterly Revenue Growth (YOY) | 0.7140 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -70,419,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 1.0280 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 74.8863 | |
| Revenue Enterprise Value | 4.9851 | |
| EBITDA Enterprise Value | -3.8634 | |
| Shares | ||
| Shares Outstanding | 189,460,000 | |
| Shares Float | 184,164,452 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.10 | |
| Insider (%) | 0.45 | |
| Institutions (%) | 38.85 | |
09/11 12:30 EST - zacks.com
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
09/03 08:00 EST - globenewswire.com
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives –
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives –
08/26 08:00 EST - globenewswire.com
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET.
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET.
08/19 09:10 EST - seekingalpha.com
Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy rating for Esperion Therapeutics, Inc. based on current execution and expanding international scope.
Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy rating for Esperion Therapeutics, Inc. based on current execution and expanding international scope.
08/16 04:09 EST - seekingalpha.com
Esperion Therapeutics: Strategically Positioned To Grow
Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough.
Esperion Therapeutics: Strategically Positioned To Grow
Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough.
08/12 21:50 EST - seekingalpha.com
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
08/12 12:47 EST - zacks.com
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates.
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates.
08/12 08:11 EST - zacks.com
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.
08/12 06:00 EST - globenewswire.com
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth –
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth –
08/07 16:30 EST - globenewswire.com
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
08/05 11:01 EST - zacks.com
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/16 08:00 EST - globenewswire.com
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –
06/28 07:00 EST - globenewswire.com
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
– OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment –
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
– OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment –
06/13 14:31 EST - investorplace.com
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.
06/11 10:00 EST - investorplace.com
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify their portfolios without breaking the bank.
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify their portfolios without breaking the bank.
06/06 12:36 EST - zacks.com
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
05/23 13:15 EST - zacks.com
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
05/23 09:00 EST - globenewswire.com
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.
05/20 06:00 EST - globenewswire.com
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.
05/20 05:43 EST - seekingalpha.com
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance.
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance.